At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 56 enrolled
Drug / intervention
AZD9668 +1 moredrug
Likely dose
AZD9668 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients With Cystic Fibrosis
In Brief
A Phase 2 clinical trial evaluating AZD9668 and AZD9668 Placebo equivalent for Cystic Fibrosis. Completed, enrolled 56 participants across 14 sites in 6 countries.
Detailed Summary
The purpose of this study is to investigate if treatment with AZD9668 for 28 days is effective in treating Cystic Fibrosis (CF) and if so how it compares to placebo (a substance which does not have any action).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesDenmark, Germany, Poland, Russia, Sweden, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2008
Enrollment StartOct 2008
Primary CompletionAug 2009
TodayJul 2026
First PostedSep 23, 2008
Enrollment StartOct 1, 2008
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 17.8 years ago
Interventions
AZD9668drug
60 mg, oral tablet, twice daily for 28 days
AZD9668 Placebo equivalentdrug
Match placebo to 60 mg, oral tablet, twice daily for 28 days